Roche One-Ups Partner
Drug giant beefs up early-stage R&D, moving into Genentech's turf.
Downer for SSRI Makers
JAMA study questions effectiveness of popular antidepressants.
Gilead Embraces Change
After axing oncology, Gilead says it's ready for new therapeutic areas.
